Glenmark Pharma USA unveils Lacosamide Oral Solution
Mahwah: Glenmark Pharmaceuticals Inc., USA has announced the launch of Lacosamide Oral Solution, 10 mg/mL.
Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.
According to IQVIA sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Lacosamide Oral Solution, 10 mg/mL, strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark’s current portfolio includes 201 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA.
Medical Dialogues team had earlier reported that Glenmark Pharmaceuticals had got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import and market the anticancer drug, Zanubrutinib Capsules 80 mg, with a local Phase III clinical trial waiver.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
Read also: Glenmark to commercialize BeiGene oncology medicines in India
